Needham Company LLC Reiterates Buy Rating for NewAmsterdam Pharma - MarketBeat
| NAMS Stock | 20.84 0.21 1.00% |
Slightly above 60% of NewAmsterdam Pharma's investor base is looking to short. The analysis of the overall investor sentiment regarding NewAmsterdam Pharma suggests that many traders are alarmed. NewAmsterdam Pharma's investing sentiment can be driven by a variety of factors including economic data, NewAmsterdam Pharma's earnings reports, geopolitical events, and overall market trends.
NewAmsterdam |
Needham Company LLC Reiterates Buy Rating for NewAmsterdam Pharma MarketBeat
Read at news.google.com
 |
NewAmsterdam Pharma Current Investor Sentiment
Panic Vs Confidence
40
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use NewAmsterdam Pharma's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward NewAmsterdam Pharma.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
NewAmsterdam Pharma Investor Sentiment by Other News Outlets
Investor sentiment, mood or attitude towards NewAmsterdam Pharma can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
NewAmsterdam Pharma Fundamental Analysis
We analyze NewAmsterdam Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of NewAmsterdam Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of NewAmsterdam Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Beta
Beta Comparative Analysis
NewAmsterdam Pharma is currently under evaluation in beta category among its peers. Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
NewAmsterdam Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with NewAmsterdam Pharma stock to make a market-neutral strategy. Peer analysis of NewAmsterdam Pharma could also be used in its relative valuation, which is a method of valuing NewAmsterdam Pharma by comparing valuation metrics with similar companies.
Peers
NewAmsterdam Pharma Related Equities
| SCPH | Scpharmaceuticals | 5.57 | ||||
| MIST | Milestone Pharmaceuticals | 0.54 | ||||
| LUMO | Lumos Pharma | 0.47 | ||||
| MCRB | Seres Therapeutics | 1.12 | ||||
| ELYM | Eliem Therapeutics | 2.91 |
Additional Tools for NewAmsterdam Stock Analysis
When running NewAmsterdam Pharma's price analysis, check to measure NewAmsterdam Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy NewAmsterdam Pharma is operating at the current time. Most of NewAmsterdam Pharma's value examination focuses on studying past and present price action to predict the probability of NewAmsterdam Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move NewAmsterdam Pharma's price. Additionally, you may evaluate how the addition of NewAmsterdam Pharma to your portfolios can decrease your overall portfolio volatility.